A

Acticor Biotech SA
PAR:ALACT

Watchlist Manager
Acticor Biotech SA
PAR:ALACT
Watchlist
Price: 0.25 EUR Market Closed
Market Cap: 3.9m EUR

Operating Margin
Acticor Biotech SA

0%
Current
0%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-17.6m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Acticor Biotech SA
Glance View

Market Cap
3.9m EUR
Industry
Biotechnology

Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

ALACT Intrinsic Value
Not Available
A
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-17.6m
/
Revenue
0
What is the Operating Margin of Acticor Biotech SA?

Based on Acticor Biotech SA's most recent financial statements, the company has Operating Margin of 0%.

Back to Top